康沣生物-B公布，与认购人(LP Investment Holdings Group及郦军先生)订立认购协议，拟以每股5.36港元 的价格向认购人发行合共746万股H股，该认购价较当日收市价折让约17.79%。此次认购所得净额约 3973万港元，其中80%将用于血管、呼吸及肿瘤介入相关的微创介入产品的研发、生产、商业化及潜在 海外业务扩张，剩余20%将用作集团一般营运资金。 （文章来源：证券时报网） ...

Core Points - The National Healthcare Security Administration (NHSA) has released a guideline for the pricing of medical services related to the vascular and lymphatic systems, consolidating existing pricing projects into 116 items, with an additional 9 surcharge items and 1 expansion item [1] - The guideline aims to standardize medical service pricing projects to improve pricing accuracy, execution, and evaluation, aligning with clinical diagnosis and treatment needs [1] - Pricing projects are categorized based on vascular differences, with specific pricing for various types of arteries and corresponding stent placement fees, enhancing compatibility of pricing projects [1] - The guideline supports the clinical application of new products and technologies, such as vascular protection devices, which are crucial for preventing serious complications during vascular surgeries [2] - The NHSA will expedite the implementation of the pricing guideline across provinces, ensuring that pricing levels are reasonable and sustainable for patients, healthcare institutions, and insurance funds [2]